Bispecific antibodies: advancing precision oncology

Herrera, Mercedes; M. Steiner, Thiago; Pretelli, Giulia; Desai, Jayesh; GARRALDA, Elena; Siu, Lillian

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Herrera, Mercedes
dc.contributor.author	M. Steiner, Thiago
dc.contributor.author	Pretelli, Giulia
dc.contributor.author	Desai, Jayesh
dc.contributor.author	GARRALDA, Elena
dc.contributor.author	Siu, Lillian
dc.date.accessioned	2025-02-10T12:12:08Z
dc.date.available	2025-02-10T12:12:08Z
dc.date.issued	2024-10
dc.identifier.citation	Herrera M, Pretelli G, Desai J, Garralda E, Siu LL, Steiner TM, et al. Bispecific antibodies: advancing precision oncology. Trends in Cancer. 2024 Oct;10(10):893-919.
dc.identifier.issn	2405-8025
dc.identifier.uri	https://hdl.handle.net/11351/12573
dc.description	Activadors de cèl·lules T; Anticossos biespecífics; Immunoteràpia
dc.description.sponsorship	We thank Alan Russell and Michael Dickinson for their helpful suggestions and review of the manuscript. M.H is supported by a Sociedad Española de Oncología Médica (SEOM) fellowship and CRIS Cancer Out-Back program; G.P is supported by the CaixaResearch Advanced Oncology Research Program supported by ‘la Caixa’ Foundation (LCF/PR/CE07/50610001); E.G is supported by the CaixaResearch Advanced Oncology Research Program supported by ‘la Caixa’ Foundation (LCF/PR/CE07/50610001); L.L.S holds the BMO Chair in Precision Cancer Genomics; T.M.S. is funded through a collaboration with Roche; L.A. is supported by the Peter Mac Foundation Discovery Partner Fellowship.
dc.language.iso	eng
dc.publisher	Elsevier
dc.relation.ispartofseries	Trends in Cancer;10(10)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Medicaments antineoplàstics - Ús terapèutic
dc.subject	Càncer - Immunoteràpia
dc.subject	Anticossos monoclonals - Ús terapèutic
dc.subject	Medicina personalitzada
dc.subject	Resistència als medicaments
dc.subject.mesh	Neoplasms
dc.subject.mesh	/drug therapy
dc.subject.mesh	Antibodies, Bispecific
dc.subject.mesh	/therapeutic use
dc.subject.mesh	Drug Resistance, Neoplasm
dc.subject.mesh	Precision Medicine
dc.subject.mesh	Antineoplastic Agents, Immunological
dc.title	Bispecific antibodies: advancing precision oncology
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1016/j.trecan.2024.07.002
dc.subject.decs	neoplasias
dc.subject.decs	/farmacoterapia
dc.subject.decs	anticuerpos biespecíficos
dc.subject.decs	/uso terapéutico
dc.subject.decs	resistencia a los antineoplásicos
dc.subject.decs	medicina de precisión
dc.subject.decs	inmunoterapia antineoplásica
dc.relation.publishversion	https://doi.org/10.1016/j.trecan.2024.07.002
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Herrera M, Siu LL] Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. [Pretelli G] Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Desai J] Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. [Garralda E] Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Steiner TM] Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
dc.identifier.pmid	39214782
dc.identifier.wos	001332577000001
dc.rights.accessrights	info:eu-repo/semantics/openAccess